Avrobio Plots Plan B After Fabry Disease Gene Therapy Problems
Lead Candidate Shelved
Executive Summary
Avrobio is sidestepping market and regulatory issues in Fabry disease by suspending development of AVR-RD-01, but says it remains focused on advancing treatment of lysosomal storage disorders with gene therapies.
You may also be interested in...
Stock Watch: 2022 Starts Badly For Biotech
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.
Sangamo's Fabry Gene Therapy May Be A STAAR In The Making
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.
Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.